GT199700091A - Celdillas de alta resistencia para el desarrollo de virus. - Google Patents

Celdillas de alta resistencia para el desarrollo de virus.

Info

Publication number
GT199700091A
GT199700091A GT199700091A GT199700091A GT199700091A GT 199700091 A GT199700091 A GT 199700091A GT 199700091 A GT199700091 A GT 199700091A GT 199700091 A GT199700091 A GT 199700091A GT 199700091 A GT199700091 A GT 199700091A
Authority
GT
Guatemala
Prior art keywords
viruses
development
high resistance
fibroblastes
production
Prior art date
Application number
GT199700091A
Other languages
English (en)
Inventor
Douglas N Foster
Linda K Foster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700091A publication Critical patent/GT199700091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA PRODUCCION Y USO DE LAS LINEAS CELULARES INMORTALIZADAS PROVENIENTES DE FIBROBLASTOS EMBRIONARIOS DE POLLO, PRIMARIOS. LAS CELULAS SON UTILES COMO SUSTRATOS PARA LA PROPAGACION DEL VIRUS, LA EXPRESION DE PROTEINA RECOMBINANTE Y LA PRODUCCION DE VIRUS RECOMBINANTES. UNA LINEA CELULAR ESPONTANEAMENTE INMORTALIZADA, DERIVADA DE FIBROBLASTOS EMBRIONARIOS DE POLLO, PRIMARIOS, QUE TIENEN LAS CARACTERISTICAS DE LA LINEA CELULAR UMNSAH DF1 Y DEPOSITADA CON LA AMERICAN TYPE CULTURE COLLECTION COMO NO. DE ACCESO CRL 12203.
GT199700091A 1996-08-13 1997-08-12 Celdillas de alta resistencia para el desarrollo de virus. GT199700091A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/696,200 US5672485A (en) 1996-08-13 1996-08-13 Immortalized cell lines for virus growth

Publications (1)

Publication Number Publication Date
GT199700091A true GT199700091A (es) 1997-08-12

Family

ID=24796108

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700091A GT199700091A (es) 1996-08-13 1997-08-12 Celdillas de alta resistencia para el desarrollo de virus.

Country Status (29)

Country Link
US (4) US5672485A (es)
EP (1) EP0920491B1 (es)
JP (3) JP3754088B2 (es)
KR (1) KR100375871B1 (es)
CN (1) CN1228119B (es)
AR (1) AR008294A1 (es)
AT (1) ATE362524T1 (es)
AU (1) AU726820B2 (es)
BR (1) BR9711067A (es)
CA (1) CA2263725C (es)
CO (1) CO4700552A1 (es)
DE (1) DE69737735T2 (es)
DK (1) DK0920491T3 (es)
DZ (1) DZ2291A1 (es)
ES (1) ES2285738T3 (es)
GT (1) GT199700091A (es)
HK (1) HK1022496A1 (es)
HN (1) HN1997000124A (es)
HU (1) HU226658B1 (es)
IL (4) IL158302A0 (es)
MA (1) MA24303A1 (es)
MY (1) MY125594A (es)
NZ (1) NZ334147A (es)
PE (1) PE108198A1 (es)
PT (1) PT920491E (es)
SV (1) SV1997000071A (es)
UY (1) UY24668A1 (es)
WO (1) WO1998006824A1 (es)
ZA (1) ZA977216B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672485A (en) * 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
US6150505A (en) * 1997-09-19 2000-11-21 Hadasit Medical Research Services & Development Ltd. Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII
US6821741B1 (en) * 2001-04-27 2004-11-23 University Hospitals Of Cleveland Cells for detection of enteroviruses
US6552172B2 (en) * 2001-08-30 2003-04-22 Habto Biotech, Inc. Fibrin nanoparticles and uses thereof
US20040023358A1 (en) * 2001-12-21 2004-02-05 Wyeth Avian embryo particulate biomass for the production of virus antigens
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US20090217404A1 (en) * 2002-09-27 2009-08-27 Lowe Scott W Cell-based RNA interference and related methods and compositions
AU2003254860A1 (en) * 2002-09-30 2004-04-23 Honda Giken Kogyo Kabushiki Kaisha Hydrogen activating apparatus
US20040170646A1 (en) * 2002-12-13 2004-09-02 Aventis Pasteur, Inc. Production of ALVAC on avian embryonic stem cells
US20060294604A1 (en) * 2003-02-17 2006-12-28 Fridman Jordan S Model for studying the role of genes in tumor resistance to chemotherapy
US20090186839A1 (en) * 2003-02-17 2009-07-23 Cold Spring Harbor Laboratory Model for studying the role of genes in chemoresistance
WO2004080162A2 (en) * 2003-03-07 2004-09-23 Avigenics, Inc. Integrase mediated avian transgenesis
US20050198700A1 (en) * 2003-03-07 2005-09-08 Avigenics, Inc. Genomic modification
US20040255345A1 (en) * 2003-03-07 2004-12-16 Rapp Jeffrey C. Production of transgenic avians
US20050034186A1 (en) * 2003-03-07 2005-02-10 Harvey Alex J. Site specific nucleic acid integration
US20050273873A1 (en) * 2003-03-07 2005-12-08 Avigenics, Inc. Genomic modification
WO2005007840A1 (en) 2003-07-22 2005-01-27 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
US20070275010A1 (en) * 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20060174364A1 (en) * 2004-03-01 2006-08-03 Avigenics, Inc. Artificial chromosomes and transchromosomic avians
US20060123504A1 (en) * 2004-12-07 2006-06-08 Avigenics, Inc. Methods of producing polyclonal antibodies
US20070190601A1 (en) * 2004-10-08 2007-08-16 Avigenics, Inc. Modified integrase and methods of use
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
EP1931698B1 (en) * 2005-10-05 2019-05-29 Alexion Pharmaceuticals, Inc. Rapid production of high titer virus
EP2029756B1 (en) 2006-06-20 2016-11-09 Transgene S.A. Process for producing poxviruses and poxvirus compositions
CN100443588C (zh) * 2006-12-11 2008-12-17 中国农业科学院北京畜牧兽医研究所 静宁鸡胚成纤维细胞系及其培养方法
US8213704B2 (en) * 2007-05-09 2012-07-03 Kla-Tencor Corp. Methods and systems for detecting defects in a reticle design pattern
EP2014279A1 (en) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0811787B1 (pt) 2007-07-03 2018-10-09 Transgene Sa usos de uma célula imortalizada e processo para imortalizar uma célula aviária
WO2009055724A2 (en) * 2007-10-26 2009-04-30 Cold Spring Harbor Laboratory High throughput methods for functionally determining rna interference efficiency
CA2715719C (en) 2008-02-25 2019-08-06 Baxter International Inc. Method for producing continuous cell lines
JP5855564B2 (ja) 2009-05-12 2016-02-09 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． オルソポックスウイルスの製造および精製方法
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
FR3008992A1 (fr) 2013-07-25 2015-01-30 Agronomique Inst Nat Rech Procede de selection d'une lignee cellulaire permissive pour la replication de virus aviaires
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
JP6546659B2 (ja) 2014-12-04 2019-07-17 インターベット インターナショナル ベー． フェー． 不死化ニワトリ胚線維芽細胞
KR101768581B1 (ko) * 2015-08-13 2017-08-17 전북대학교 산학협력단 자발적 불멸화된 체세포의 단일 세포로부터 리프로그래밍 세포주의 제조방법
US20190144831A1 (en) * 2015-12-11 2019-05-16 Intervet Inc. Immortalised chicken embryonic epithelial kidney cells
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US20200179507A1 (en) 2016-11-17 2020-06-11 Regents Of The University Of Minnesota Immortalized cell lines and methods of use
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
CN107858323B (zh) * 2017-11-08 2020-10-09 广东省生物资源应用研究所 一种红耳龟胚胎成纤维细胞系及其构建方法
CN109234239B (zh) * 2018-07-13 2021-09-14 广东永顺生物制药股份有限公司 一种鸭瘟病毒的培养方法
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
WO2021123104A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Multivalent hvt vector vaccine
CN115243717A (zh) 2020-03-12 2022-10-25 巴法里安诺迪克有限公司 改善痘病毒稳定性的组合物
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
CN116528893A (zh) 2020-09-07 2023-08-01 英特维特国际股份有限公司 用于ha抗体阳性靶标的ha茎疫苗
WO2022136623A1 (en) 2020-12-24 2022-06-30 Intervet International B.V. Multivalent hvt vector vaccine
WO2023285489A1 (en) 2021-07-13 2023-01-19 Intervet International B.V. Overcoming antibody-interference in avians
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213946A1 (en) 2022-05-05 2023-11-09 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3058438B2 (ja) * 1990-10-19 2000-07-04 財団法人化学及血清療法研究所 ヒト肝臓組織特異的ウイルスの感染可能な霊長類の不死化肝細胞およびその調製方法
US5672485A (en) * 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth

Also Published As

Publication number Publication date
ES2285738T3 (es) 2007-11-16
IL158301A0 (en) 2004-05-12
MY125594A (en) 2006-08-30
CN1228119B (zh) 2012-04-04
CA2263725C (en) 2002-10-15
CN1228119A (zh) 1999-09-08
IL158303A0 (en) 2004-05-12
HK1022496A1 (en) 2000-08-11
AR008294A1 (es) 1999-12-29
KR20000029968A (ko) 2000-05-25
EP0920491B1 (en) 2007-05-16
UY24668A1 (es) 1998-02-02
US5985642A (en) 1999-11-16
IL128511A0 (en) 2000-01-31
HUP0000188A3 (en) 2005-11-28
BR9711067A (pt) 1999-08-17
JP3754088B2 (ja) 2006-03-08
HN1997000124A (es) 1999-03-19
NZ334147A (en) 2000-08-25
DK0920491T3 (da) 2007-09-17
JP2005118053A (ja) 2005-05-12
US5879924A (en) 1999-03-09
MA24303A1 (fr) 1998-04-01
ATE362524T1 (de) 2007-06-15
PT920491E (pt) 2007-07-27
SV1997000071A (es) 2000-07-06
DE69737735T2 (de) 2008-01-31
EP0920491A1 (en) 1999-06-09
AU726820B2 (en) 2000-11-23
JP2006320328A (ja) 2006-11-30
DZ2291A1 (fr) 2002-12-25
US6207415B1 (en) 2001-03-27
IL158302A0 (en) 2004-05-12
CO4700552A1 (es) 1998-12-29
WO1998006824A1 (en) 1998-02-19
KR100375871B1 (ko) 2003-03-10
CA2263725A1 (en) 1998-02-19
US5672485A (en) 1997-09-30
ZA977216B (en) 1998-02-19
JP2000516095A (ja) 2000-12-05
IL128511A (en) 2004-06-01
DE69737735D1 (de) 2007-06-28
HUP0000188A2 (hu) 2000-06-28
HU226658B1 (en) 2009-06-29
PE108198A1 (es) 1999-01-21
AU4069197A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
GT199700091A (es) Celdillas de alta resistencia para el desarrollo de virus.
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE205866T1 (de) Hydrophile, hochquellfähige hydrogele
DE69634640D1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
DE50012863D1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
ES2186796T3 (es) Procedimiento para el tratamiento del asma alergica.
EE03955B1 (et) Nukleiinhappe kasutamine ravimi valmistamiseks imetaja reproduktiivtrakti vähemalt mõne raku transfekteerimiseks
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69736858D1 (de) Unsterbliche vogelzellen
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ATE354643T1 (de) Immortalisierte geflügelzellinien
DE69535337D1 (de) Transkriptionsfaktor e2f-5
MX174187B (es) Recipiente autoportante en especial para ser empleado como cuba electrolitica
DE69826029D1 (de) Acetyl-coa-carboxylase von candida albicans
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
DE69934399D1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen
ECSP972224A (es) Celulas inmortalizadas para cultivo de virus